<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01611883</url>
  </required_header>
  <id_info>
    <org_study_id>P06541</org_study_id>
    <secondary_id>MK-0653-367</secondary_id>
    <nct_id>NCT01611883</nct_id>
  </id_info>
  <brief_title>A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)</brief_title>
  <official_title>Examination of the Effect of Ezetimibe on Glucose Metabolism - Randomized, Double-blind, Placebo-controlled Study in Type 2 Diabetes Mellitus Patients With Hypercholesterolemia - Phase 4, Protocol No. 367 (Also Known as SCH 58235, P06541)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effect of ezetimibe on glucose metabolism in participants with
      Type 2 diabetes and hypercholesterolemia.The primary hypothesis is that change in glycated
      hemoglobin (HbA1c) from baseline in the ezetimibe treatment group will be non-inferior to the
      placebo control group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2, 2012</start_date>
  <completion_date type="Actual">January 16, 2014</completion_date>
  <primary_completion_date type="Actual">January 16, 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Glycated Hemoglobin (HbA1c) From Baseline</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>HbA1c is blood marker used to report average blood glucose levels over a prolonged period of time and is reported as a percentage (%). HbA1C was measured at baseline and after 24 weeks of study drug administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Glycoalbumin From Baseline</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Glycoalbumin is a blood marker used to assess blood glucose control over time and is reported as a percentage (%). Serum glycoalbumin levels were assessed at baseline and after 24 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG) From Baseline</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Plasma glucose levels were assessed after an overnight fast at baseline and after 24 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Event (AE) &quot;Exacerbation of Diabetes&quot;</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>The Investigator took into account a participant's index of blood glucose control, diabetes medications, and compliance to diet and exercise therapy to assess overall control of the participant's diabetes and to determine if the participant's diabetes worsened. Participants who experienced the AE &quot;Exacerbation of Diabetes &quot; (verbatim term) were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Changes in Diabetes Medications Due to Worsening of Diabetes</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The percentage of participants who had changes to their medications used to treat their diabetes, other than small changes in insulin dosing (± 5 Units), were reported and summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>LDL-C levels measured at baseline and after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Cholesterol (TC) From Baseline</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>TC levels measured at Baseline and after 24 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Triglycerides From Baseline</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Triglycerides levels measured at baseline and after 24 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>HDL-C levels measured at baseline and after 24 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Non-HDL-cholesterol From Baseline</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Non-HDL-C levels measured at baseline and after 24 weeks of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg oral dose once daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match ezetimibe orally once daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>10 mg oral dose once daily for 24 weeks</description>
    <arm_group_label>Ezetimibe</arm_group_label>
    <other_name>MK-0653</other_name>
    <other_name>SCH 058235</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match ezetimibe orally once daily for 24 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have hypercholesterolemia (high cholesterol) and have been diagnosed with type 2
             diabetes that is being treated with oral anti-diabetic drugs or insulin or both.

          -  No change in the medication (drugs, dose and administration) for the treatment of
             diabetes within previous 12 weeks with exception of small changes in insulin dosing

          -  No change in diet and exercise therapy within previous 4 weeks

        Exclusion Criteria:

          -  Coexisting disease (hemoglobinopathy, hemolytic anemia, etc.) that may affect HbA1c
             measurement

          -  Homozygous or heterozygous familial hypercholesterolemia

          -  Previously received ezetimibe

          -  Hypercholesterolemia associated with: hypothyroidism, obstructive gall bladder or
             biliary disease, chronic renal failure or pancreatitis

          -  Hyperlipidemia caused by medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <results_reference>
    <citation>Saito I, Azuma K, Kakikawa T, Oshima N, Hanson ME, Tershakovec AM. A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia. Lipids Health Dis. 2015 May 1;14:40. doi: 10.1186/s12944-015-0036-z.</citation>
    <PMID>25929253</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2012</study_first_submitted>
  <study_first_submitted_qc>June 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <results_first_submitted>December 9, 2014</results_first_submitted>
  <results_first_submitted_qc>December 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2014</results_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=P06541&amp;kw=P06541&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ezetimibe</title>
          <description>10 mg oral dose once daily for 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo to match ezetimibe orally once daily for 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ezetimibe</title>
          <description>10 mg oral dose once daily for 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo to match ezetimibe orally once daily for 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="77"/>
            <count group_id="B3" value="152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.3" spread="10.8"/>
                    <measurement group_id="B2" value="60.0" spread="9.7"/>
                    <measurement group_id="B3" value="59.6" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Glycated Hemoglobin (HbA1c) From Baseline</title>
        <description>HbA1c is blood marker used to report average blood glucose levels over a prolonged period of time and is reported as a percentage (%). HbA1C was measured at baseline and after 24 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Per Protocol Set defined as all randomized participants meeting inclusion criteria who were not excluded from the Full Analysis Set and were at least 75% compliant with study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>10 mg oral dose once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe orally once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycated Hemoglobin (HbA1c) From Baseline</title>
          <description>HbA1c is blood marker used to report average blood glucose levels over a prolonged period of time and is reported as a percentage (%). HbA1C was measured at baseline and after 24 weeks of study drug administration.</description>
          <population>Per Protocol Set defined as all randomized participants meeting inclusion criteria who were not excluded from the Full Analysis Set and were at least 75% compliant with study medication.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" lower_limit="0.11" upper_limit="0.34"/>
                    <measurement group_id="O2" value="0.14" lower_limit="0.03" upper_limit="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ezetimibe treatment group will be considered non-inferior to the placebo control group if the upper bound of the two-sided 95% confidence interval (CI) of the between-treatment difference (ezetimibe minus placebo) in means for change in HbA1c from baseline to the end of treatment does not exceed 0.5%.</non_inferiority_desc>
            <param_type>Difference in Least-squares Means</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
            <estimate_desc>ezetimibe minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glycoalbumin From Baseline</title>
        <description>Glycoalbumin is a blood marker used to assess blood glucose control over time and is reported as a percentage (%). Serum glycoalbumin levels were assessed at baseline and after 24 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Per Protocol Set defined as all randomized participants meeting inclusion criteria who were not excluded from the Full Analysis Set and were at least 75% compliant with study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>10 mg oral dose once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe orally once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycoalbumin From Baseline</title>
          <description>Glycoalbumin is a blood marker used to assess blood glucose control over time and is reported as a percentage (%). Serum glycoalbumin levels were assessed at baseline and after 24 weeks of study drug administration.</description>
          <population>Per Protocol Set defined as all randomized participants meeting inclusion criteria who were not excluded from the Full Analysis Set and were at least 75% compliant with study medication.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.37" upper_limit="0.34"/>
                    <measurement group_id="O2" value="-0.02" lower_limit="-0.37" upper_limit="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Least-squares Means</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
            <estimate_desc>ezetimibe minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose (FPG) From Baseline</title>
        <description>Plasma glucose levels were assessed after an overnight fast at baseline and after 24 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Per Protocol Set defined as all randomized participants meeting inclusion criteria who were not excluded from the Full Analysis Set and were at least 75% compliant with study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>10 mg oral dose once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe orally once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (FPG) From Baseline</title>
          <description>Plasma glucose levels were assessed after an overnight fast at baseline and after 24 weeks of study drug administration.</description>
          <population>Per Protocol Set defined as all randomized participants meeting inclusion criteria who were not excluded from the Full Analysis Set and were at least 75% compliant with study medication.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="1.1" upper_limit="12.1"/>
                    <measurement group_id="O2" value="11.4" lower_limit="6.1" upper_limit="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Least-squares Means</param_type>
            <param_value>-4.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.1</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
            <estimate_desc>ezetimibe minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Event (AE) &quot;Exacerbation of Diabetes&quot;</title>
        <description>The Investigator took into account a participant’s index of blood glucose control, diabetes medications, and compliance to diet and exercise therapy to assess overall control of the participant’s diabetes and to determine if the participant’s diabetes worsened. Participants who experienced the AE “Exacerbation of Diabetes ” (verbatim term) were recorded.</description>
        <time_frame>up to 24 weeks</time_frame>
        <population>All Subjects Treated (AST) Population defined as all participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>10 mg oral dose once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe orally once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Event (AE) &quot;Exacerbation of Diabetes&quot;</title>
          <description>The Investigator took into account a participant’s index of blood glucose control, diabetes medications, and compliance to diet and exercise therapy to assess overall control of the participant’s diabetes and to determine if the participant’s diabetes worsened. Participants who experienced the AE “Exacerbation of Diabetes ” (verbatim term) were recorded.</description>
          <population>All Subjects Treated (AST) Population defined as all participants who received at least 1 dose of study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of percentage difference between ezetimibe and placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.779</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Changes in Diabetes Medications Due to Worsening of Diabetes</title>
        <description>The percentage of participants who had changes to their medications used to treat their diabetes, other than small changes in insulin dosing (± 5 Units), were reported and summarized.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>AST Population defined as all participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>10 mg oral dose once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe orally once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Changes in Diabetes Medications Due to Worsening of Diabetes</title>
          <description>The percentage of participants who had changes to their medications used to treat their diabetes, other than small changes in insulin dosing (± 5 Units), were reported and summarized.</description>
          <population>AST Population defined as all participants who received at least 1 dose of study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of percentage difference between ezetimibe and placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.365</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline</title>
        <description>LDL-C levels measured at baseline and after 24 weeks of treatment</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full Analysis Set (FAS) defined as all enrolled participants who received at least 1 dose of study drug and baseline and follow-up data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>10 mg oral dose once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe orally once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline</title>
          <description>LDL-C levels measured at baseline and after 24 weeks of treatment</description>
          <population>Full Analysis Set (FAS) defined as all enrolled participants who received at least 1 dose of study drug and baseline and follow-up data available.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.79" lower_limit="-25.81" upper_limit="-19.78"/>
                    <measurement group_id="O2" value="-1.75" lower_limit="-4.73" upper_limit="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal analysis of covariance</method>
            <method_desc>Treatment group, HbA1c level, insulin use, time, and “time × treatment group” interaction as factors, and baseline as covariate</method_desc>
            <param_type>Difference in Least-squares Means</param_type>
            <param_value>-21.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.06</ci_lower_limit>
            <ci_upper_limit>-17.03</ci_upper_limit>
            <estimate_desc>ezetimibe minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Cholesterol (TC) From Baseline</title>
        <description>TC levels measured at Baseline and after 24 weeks of treatment.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>FAS defined as all enrolled participants who received at least 1 dose of study drug and baseline and follow-up data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>10 mg oral dose once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe orally once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Cholesterol (TC) From Baseline</title>
          <description>TC levels measured at Baseline and after 24 weeks of treatment.</description>
          <population>FAS defined as all enrolled participants who received at least 1 dose of study drug and baseline and follow-up data available.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.01" lower_limit="-17.34" upper_limit="-12.68"/>
                    <measurement group_id="O2" value="-1.47" lower_limit="-3.77" upper_limit="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal analysis of covariance</method>
            <method_desc>Treatment group, HbA1c level, insulin use, time, and “time × treatment group” interaction as factors, and baseline as covariate</method_desc>
            <param_type>Difference in Least-squares Means</param_type>
            <param_value>-13.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.66</ci_lower_limit>
            <ci_upper_limit>-10.42</ci_upper_limit>
            <estimate_desc>ezetimibe minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Triglycerides From Baseline</title>
        <description>Triglycerides levels measured at baseline and after 24 weeks of treatment.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full Analysis Set (FAS) defined as all enrolled participants who received at least 1 dose of study drug and baseline and follow-up data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>10 mg oral dose once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe orally once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Triglycerides From Baseline</title>
          <description>Triglycerides levels measured at baseline and after 24 weeks of treatment.</description>
          <population>Full Analysis Set (FAS) defined as all enrolled participants who received at least 1 dose of study drug and baseline and follow-up data available.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.52" lower_limit="-14.97" upper_limit="-0.08"/>
                    <measurement group_id="O2" value="3.83" lower_limit="-3.57" upper_limit="11.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>Longitudinal Analysis of Covariance</method>
            <method_desc>Treatment group, HbA1c level, insulin use, time, and “time × treatment group” interaction as factors, and baseline as covariate</method_desc>
            <param_type>Difference in Least-squares Means</param_type>
            <param_value>-11.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.27</ci_lower_limit>
            <ci_upper_limit>-1.44</ci_upper_limit>
            <estimate_desc>ezetimibe minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline</title>
        <description>HDL-C levels measured at baseline and after 24 weeks of treatment.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full Analysis Set (FAS) defined as all enrolled participants who received at least 1 dose of study drug and baseline and follow-up data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>10 mg oral dose once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe orally once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline</title>
          <description>HDL-C levels measured at baseline and after 24 weeks of treatment.</description>
          <population>Full Analysis Set (FAS) defined as all enrolled participants who received at least 1 dose of study drug and baseline and follow-up data available.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" lower_limit="0.77" upper_limit="6.96"/>
                    <measurement group_id="O2" value="1.41" lower_limit="-1.64" upper_limit="4.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.246</p_value>
            <method>Longitudinal Analysis of Covariance</method>
            <method_desc>Treatment group, HbA1c level, insulin use, time, and “time × treatment group” interaction as factors, and baseline as covariate</method_desc>
            <param_type>Difference in Least-squares Means</param_type>
            <param_value>2.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.71</ci_lower_limit>
            <ci_upper_limit>6.61</ci_upper_limit>
            <estimate_desc>ezetimibe minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Non–HDL-cholesterol From Baseline</title>
        <description>Non-HDL-C levels measured at baseline and after 24 weeks of treatment.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full Analysis Set (FAS) defined as all enrolled participants who received at least 1 dose of study drug and baseline and follow-up data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>10 mg oral dose once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe orally once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Non–HDL-cholesterol From Baseline</title>
          <description>Non-HDL-C levels measured at baseline and after 24 weeks of treatment.</description>
          <population>Full Analysis Set (FAS) defined as all enrolled participants who received at least 1 dose of study drug and baseline and follow-up data available.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.32" lower_limit="-24.05" upper_limit="-18.59"/>
                    <measurement group_id="O2" value="-2.25" lower_limit="-4.95" upper_limit="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal Analysis of Covariance</method>
            <method_desc>Treatment group, HbA1c level, insulin use, time, and “time × treatment group” interaction as factors, and baseline as covariate</method_desc>
            <param_type>Difference in Least-squares Means</param_type>
            <param_value>-19.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.71</ci_lower_limit>
            <ci_upper_limit>-15.43</ci_upper_limit>
            <estimate_desc>ezetimibe minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 24 weeks for non-serious adverse events (AEs); up to 28 weeks for serious AEs</time_frame>
      <desc>All Subjects Treated (AST) Population defined as all participants who received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ezetimibe</title>
          <description>10 mg oral dose once daily for 24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo to match ezetimibe orally once daily for 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="75"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="14" subjects_affected="7" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

